Rapid Micro Biosystems (RPID) Debt Ratio (2020 - 2026)

Rapid Micro Biosystems' (RPID) quarterly Debt Ratio came in at 0.31 in Q1 2026, up 20.99% quarter-over-quarter from 0.25 in Q4 2025.

Rapid Micro Biosystems (RPID) Debt Ratio (2020 - 2026) Analysis & Trends

Rapid Micro Biosystems has disclosed Debt Ratio across 4 years of filings, most recently posting 0.31 for Q1 2026.

Debt Ratio for Q1 2026 came in at 0.31, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 0.31 (changed N/A YoY), and the FY2025 annual result was 0.25, changed N/A from the prior year.
Debt Ratio came in at 0.31 for Q1 2026 at Rapid Micro Biosystems, up from 0.25 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.31 in Q1 2026 to a low of 0.22 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	0.31
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	0.32
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	0.31
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	0.25
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	0.04
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	0.30
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	0.27
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	0.18
10	Rapid Micro Biosystems	77.24 Mn	54.29 Mn	371,000.00	0.31

Download Data